En el cuarto trimestre de 2025, el gigante farmacéutico reconocido por sus medicamentos para adelgazar, reportó ingresos de 19 mil 290 mdd

Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs